First Allied Advisory Services Inc. trimmed its stake in shares of iShares US Pharmaceuticals ETF (NYSEARCA:IHE) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,732 shares of the company’s stock after selling 102 shares during the period. First Allied Advisory Services Inc. owned about 0.11% of iShares US Pharmaceuticals ETF worth $387,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of IHE. Matthew Goff Investment Advisor LLC raised its holdings in shares of iShares US Pharmaceuticals ETF by 11,619.0% during the third quarter. Matthew Goff Investment Advisor LLC now owns 677,593 shares of the company’s stock worth $5,782,000 after acquiring an additional 671,811 shares during the period. Colony Group LLC acquired a new position in shares of iShares US Pharmaceuticals ETF during the 4th quarter worth about $7,839,000. Biegel & Waller LLC acquired a new position in shares of iShares US Pharmaceuticals ETF during the 4th quarter worth about $5,408,000. Citadel Advisors LLC acquired a new position in shares of iShares US Pharmaceuticals ETF during the 3rd quarter worth about $2,952,000. Finally, Ferguson Wellman Capital Management Inc. acquired a new position in shares of iShares US Pharmaceuticals ETF during the 4th quarter worth about $1,485,000.
Shares of iShares US Pharmaceuticals ETF stock traded up $1.21 during trading on Friday, hitting $149.31. 3,103 shares of the stock were exchanged, compared to its average volume of 10,940. iShares US Pharmaceuticals ETF has a 1-year low of $131.91 and a 1-year high of $170.26.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/ishares-us-pharmaceuticals-etf-ihe-stake-lessened-by-first-allied-advisory-services-inc.html.
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for iShares US Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares US Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.